Recombinant vaccines for hepatitis E

Trends Mol Med. 2001 Oct;7(10):462-6. doi: 10.1016/s1471-4914(01)02106-2.

Abstract

Hepatitis E virus causes epidemics of acute hepatitis in many developing countries. It infrequently causes disease in developed countries, but avirulent strains might circulate. Some evidence suggests that hepatitis E might be a zoonosis. There is probably only a single serotype. A candidate vaccine consisting of baculovirus-expressed recombinant capsid protein protected macaques from hepatitis E--it passed phase I clinical trials and is currently scheduled for phase II/III clinical trials.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Hepatitis E / immunology*
  • Hepatitis E / prevention & control*
  • Hepatitis E virus / genetics
  • Hepatitis E virus / immunology
  • Hepatitis E virus / physiology
  • Humans
  • Immunotherapy, Active / methods
  • Immunotherapy, Active / trends
  • Recombinant Proteins / immunology
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology*
  • Viral Hepatitis Vaccines / genetics
  • Viral Hepatitis Vaccines / immunology*
  • Viral Proteins / genetics
  • Viral Proteins / immunology

Substances

  • ORF2 protein, Hepatitis E virus
  • Recombinant Proteins
  • Vaccines, Synthetic
  • Viral Hepatitis Vaccines
  • Viral Proteins